Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 10Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Urinary Bladder Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lymphoma 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1HER-2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Paclitaxel 20Carboplatin 16liposomal doxorubicin 10Bevacizumab 10Gemcitabine 8Topotecan 7Taxes 7Cisplatin 7pembrolizumab 6Doxorubicin 5Cyclophosphamide 5Nivolumab 4fludarabine 3Oxaliplatin 3Immunoglobulin G 3Hyperthermic Intraperitoneal Chemotherapy 3Disulfides 3Cytoreduction Surgical Procedures 3trebananib 2talazoparib 2rucaparib 2peginterferon alfa-2b 2olaparib 2fludarabine phosphate 2aldesleukin 2Surgical Procedures, Operative 2STA 9090 2Platinum 2Lenalidomide 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Fallopian Tube Neoplasms × eribulin × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡